Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study - Quiz - MDSpire

Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study

  • By

  • Anuradha Jayaram

  • Memuna Rashid

  • Alison H. M. Reid

  • Francesco Orlando

  • Suparna Thakali

  • Leila Zakka

  • Miriam Goncalves

  • Jacqueline O’Dwyer

  • Constantine Alifrangis

  • Rob Jones

  • Elias Pintus

  • Sarah Needleman

  • Diletta Bianchini

  • Anna Wingate

  • Kenrick Ng

  • Mark Linch

  • Ursula McGovern

  • John Staffurth

  • Simon J. Crabb

  • Susannah Brock

  • Alison Birtle

  • Osvaldas Vainauskas

  • Gianmarco Leone

  • Millenn Chiwewe

  • Allan Hackshaw

  • Andre Lopes

  • Daniel Wetterskog

  • Francesca Demichelis

  • Gerhardt Attard

  • May 15, 2026

  • 0 min

Share

Original Source(s)

Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study

  • by Anuradha Jayaram, Memuna Rashid, Alison H. M. Reid, Francesco Orlando, Suparna Thakali, Leila Zakka, Miriam Goncalves, Jacqueline O’Dwyer, Constantine Alifrangis, Rob Jones, Elias Pintus, Sarah Needleman, Diletta Bianchini, Anna Wingate, Kenrick Ng, Mark Linch, Ursula McGovern, John Staffurth, Simon J. Crabb, Susannah Brock, Alison Birtle, Osvaldas Vainauskas, Gianmarco Leone, Millenn Chiwewe, Allan Hackshaw, Andre Lopes, Daniel Wetterskog, Francesca Demichelis, Gerhardt Attard

  • May 15, 2026

Related Content

Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report

FOXA2 in cancer: from fundamental biology to clinical translation

Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report